Symbiotec Pharmalab Limited has filed its DRHP with SEBI, proposing an IPO of up to ₹2,180 crore, comprising both fresh issue and offer-for-sale components.
The company plans a fresh issue of equity shares aggregating ₹150 crore, while existing shareholders will offload shares worth up to ₹2,030 crore through the OFS. The shares are proposed to be listed on India’s leading stock exchanges.
As per the DRHP, the company intends to use fresh issue proceeds primarily for debt repayment, which is expected to strengthen its balance sheet.
Symbiotec Pharmalab focuses on manufacturing active pharmaceutical ingredients (APIs) and has a strong presence in corticosteroid and steroidal-hormone segments. The DRHP notes that the company commanded a global volume market share of over 36% in corticosteroid APIs in FY25.
